Mr. Kenneth Galbraith reports
LIMINAL BIOSCIENCES JOINS COVIG PLASMA ALLIANCE TO CONTRIBUTE TO DEVELOPMENT OF POTENTIAL NEW COVID-19 THERAPY
Liminal Biosciences Inc.'s subsidiary, Prometic Plasma Resources, has joined the CoVIg-19 Plasma Alliance to contribute to the acceleration of the development of a potential new therapy for COVID-19.
"We are proud to be joining plasma companies Takeda, CSL Behring, ADMA Biologics, Biopharma Plasma, Biotest, BPL, GC Pharma, LFB, Octapharma, Sanquin, and other contributors and supporters of the CoVIg-19 Plasma Alliance in a unique partnership of the world's leading plasma-derived therapeutic companies to collaborate and co-ordinate efforts during the COVID-19 pandemic," stated Kenneth Galbraith, chief executive officer of Liminal BioSciences. "The CoVIg-19 Plasma Alliance aims to put public and patient health first by working together, and is combining all efforts to collect convalescent plasma to develop a potential plasma-derived COVID-19 therapy. We hope that our expertise in developing plasma-based therapeutics and our plasma collection centres in the U.S. and Canada will go some way to contributing to this important cause."
Individuals interested in donating plasma can visit Prometic Plasma's website to find the nearest Prometic Plasma Resources plasma collection centre to their location.
About Liminal Biosciences Inc.
Liminal Biosciences is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing novel treatments for patients suffering from diseases related to fibrosis, including respiratory, liver and kidney diseases that have high unmet medical need.
We seek Safe Harbor.
© 2020 Canjex Publishing Ltd. All rights reserved.